Skip to main content
Fig. 9 | Journal of Ovarian Research

Fig. 9

From: Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer

Fig. 9

Drug sensitivity analysis in different risk groups based on FIRLs signature. a IC50 levels of Docetaxel; b IC50 levels of Doxorubicin; c IC50 levels of Etoposide; d IC50 levels of Paclitaxel; e IC50 levels of Gemcitabine; f IC50 levels of Bleomycin; g IC50 levels of Cisplatin

Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us